双抗-话题@MedSci

#双抗#

81篇内容 | 3590人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2227840, encodeId=e3f7222e8409f, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a> <a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=BMJ子刊：中国学者揭示症状发作后 72 小时内轻度卒中双联抗血小板治疗的最佳持续时间：一项前瞻性队列研究, objectType=article, longId=844640, objectId=b38684464076, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240704/1720065244146_92910.jpg, objectUrl=/article/show_article.do?id=b38684464076, replyNumber=0, likeNumber=163, createdTime=2024-09-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b38684464076, moduleTitle=BMJ子刊：中国学者揭示症状发作后 72 小时内轻度卒中双联抗血小板治疗的最佳持续时间：一项前瞻性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b38684464076)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205068, encodeId=35a12205068c7, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【Blood】META分析：LBCL的≥3线治疗中CAR-T和双抗孰优孰劣？, objectType=article, longId=826091, objectId=0a13826091f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240516/1715849183538_5579292.jpg, objectUrl=/article/show_article.do?id=0a13826091f3, replyNumber=0, likeNumber=135, createdTime=2024-05-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0a13826091f3, moduleTitle=【Blood】META分析：LBCL的≥3线治疗中CAR-T和双抗孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a13826091f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1487286, encodeId=6c57148e2863c, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, objectType=article, longId=732675, objectId=84ece326750e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ece326750e, replyNumber=0, likeNumber=128, createdTime=2022-07-19, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ece326750e, moduleTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ece326750e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487285, encodeId=2c36148e2856b, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=脑血管重度狭窄：阿司匹林联合氯吡格雷，双抗口服多久？, objectType=article, longId=731275, objectId=2fd3e3127532, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fd3e3127532, replyNumber=0, likeNumber=130, createdTime=2022-07-06, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fd3e3127532, moduleTitle=脑血管重度狭窄：阿司匹林联合氯吡格雷，双抗口服多久？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fd3e3127532)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487284, encodeId=ea86148e28473, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Science Advances：用癌症患者自身抗体生成双抗，用于清除肿瘤, objectType=article, longId=728911, objectId=d373e289117f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d373e289117f, replyNumber=0, likeNumber=173, createdTime=2022-06-10, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d373e289117f, moduleTitle=Science Advances：用癌症患者自身抗体生成双抗，用于清除肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d373e289117f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487283, encodeId=9a27148e2836e, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=肿瘤免疫明星靶点：靶向CD137的双抗策略, objectType=article, longId=726917, objectId=8018e269177f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8018e269177f, replyNumber=0, likeNumber=121, createdTime=2022-05-17, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8018e269177f, moduleTitle=肿瘤免疫明星靶点：靶向CD137的双抗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8018e269177f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487282, encodeId=9177148e2828e, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=卒中 | 缺血性卒中使用双抗的10种情况, objectType=article, longId=725720, objectId=4a3ee257202a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a3ee257202a, replyNumber=0, likeNumber=151, createdTime=2022-04-30, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a3ee257202a, moduleTitle=卒中 | 缺血性卒中使用双抗的10种情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a3ee257202a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487281, encodeId=f3f4148e28143, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Neurology：双联抗血小板治疗2周后应该更换为联合西洛他唑的双抗？, objectType=article, longId=724281, objectId=7bc8e242810c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bc8e242810c, replyNumber=0, likeNumber=111, createdTime=2022-04-16, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bc8e242810c, moduleTitle=Neurology：双联抗血小板治疗2周后应该更换为联合西洛他唑的双抗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bc8e242810c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487280, encodeId=d4c8148e280b2, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=JAMA N：DWI阳性者才能从双抗治疗中获益？, objectType=article, longId=724043, objectId=0d01e2404313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d01e2404313, replyNumber=0, likeNumber=147, createdTime=2022-04-13, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d01e2404313, moduleTitle=JAMA N：DWI阳性者才能从双抗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d01e2404313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487279, encodeId=6151148e279aa, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=双抗期间院外出血风险评估（PRECISE-DAPT score）, objectType=article, longId=300836, objectId=b71930083632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b71930083632, replyNumber=0, likeNumber=111, createdTime=2022-03-17, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b71930083632, moduleTitle=双抗期间院外出血风险评估（PRECISE-DAPT score）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b71930083632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487278, encodeId=3e52148e278f3, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=阿司匹林 + 替格瑞洛，适合中国人群的双抗治疗！, objectType=article, longId=300776, objectId=c82a300e76f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c82a300e76f1, replyNumber=0, likeNumber=142, createdTime=2022-03-16, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c82a300e76f1, moduleTitle=阿司匹林 + 替格瑞洛，适合中国人群的双抗治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c82a300e76f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487277, encodeId=e338148e2772b, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Cell：复旦大学研究人员发现可雾化吸入的广谱抗新冠全人源纳米双抗药物, objectType=article, longId=300549, objectId=5e9e30054930, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e9e30054930, replyNumber=0, likeNumber=129, createdTime=2022-03-13, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e9e30054930, moduleTitle=Cell：复旦大学研究人员发现可雾化吸入的广谱抗新冠全人源纳米双抗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e9e30054930)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487276, encodeId=f658148e2767b, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Stroke：穿支动脉粥样硬化病的双抗联合阿加曲班治疗, objectType=article, longId=299187, objectId=5cc929918e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc929918e7a, replyNumber=0, likeNumber=166, createdTime=2022-02-21, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc929918e7a, moduleTitle=Stroke：穿支动脉粥样硬化病的双抗联合阿加曲班治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cc929918e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487275, encodeId=f3f8148e275b2, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Annals of Neurology：天坛医院，轻度脑中风后，双抗血小板治疗，出血风险如何？, objectType=article, longId=295696, objectId=f37e2956966a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f37e2956966a, replyNumber=0, likeNumber=165, createdTime=2022-02-17, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f37e2956966a, moduleTitle=Annals of Neurology：天坛医院，轻度脑中风后，双抗血小板治疗，出血风险如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f37e2956966a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487274, encodeId=3cad148e27468, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药, objectType=article, longId=221841, objectId=a33c221841fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a33c221841fa, replyNumber=0, likeNumber=114, createdTime=2021-12-12, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a33c221841fa, moduleTitle=凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a33c221841fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487273, encodeId=941a148e273f9, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=君实生物JS016新冠双抗体疗法获得授权成为全球且唯一可在12岁以下人群中紧急使用的中和抗体疗法, objectType=article, longId=221620, objectId=04b3221620c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04b3221620c6, replyNumber=0, likeNumber=136, createdTime=2021-12-08, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04b3221620c6, moduleTitle=君实生物JS016新冠双抗体疗法获得授权成为全球且唯一可在12岁以下人群中紧急使用的中和抗体疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04b3221620c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487272, encodeId=9f8b148e27258, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Nature Communications：PD-1/CD137双抗效果优异，安全性良好, objectType=article, longId=220377, objectId=c40c2203e71e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c40c2203e71e, replyNumber=0, likeNumber=132, createdTime=2021-11-16, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40c2203e71e, moduleTitle=Nature Communications：PD-1/CD137双抗效果优异，安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c40c2203e71e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487271, encodeId=e5fb148e27115, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=JAMA N：NIHSS评分4和5分患者双抗治疗的证据, objectType=article, longId=218545, objectId=2ea521854565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea521854565, replyNumber=0, likeNumber=152, createdTime=2021-10-15, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea521854565, moduleTitle=JAMA N：NIHSS评分4和5分患者双抗治疗的证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ea521854565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487270, encodeId=9ace148e2705e, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, objectType=article, longId=216944, objectId=046e21694492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046e21694492, replyNumber=0, likeNumber=133, createdTime=2021-09-12, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046e21694492, moduleTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046e21694492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487269, encodeId=ed2b148e269f5, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=乳腺癌抗体治疗格局：单抗/双抗/ADC百花齐放！, objectType=article, longId=216613, objectId=bc6121661333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc6121661333, replyNumber=0, likeNumber=132, createdTime=2021-09-04, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc6121661333, moduleTitle=乳腺癌抗体治疗格局：单抗/双抗/ADC百花齐放！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc6121661333)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

双抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#急性卒中# #双抗#

BMJ子刊：中国学者揭示症状发作后 72 小时内轻度卒中双联抗血小板治疗的最佳持续时间：一项前瞻性队列研究

2024-09-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤# #双抗# #CAR-T#

【Blood】META分析：LBCL的≥3线治疗中CAR-T和双抗孰优孰劣？

2024-05-16发表于上海

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效

2022-07-19

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

脑血管重度狭窄：阿司匹林联合氯吡格雷，双抗口服多久？

2022-07-06

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Science Advances：用癌症患者自身抗体生成双抗，用于清除肿瘤

2022-06-10

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

肿瘤免疫明星靶点：靶向CD137的双抗策略

2022-05-17

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

卒中 | 缺血性卒中使用双抗的10种情况

2022-04-30

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Neurology：双联抗血小板治疗2周后应该更换为联合西洛他唑的双抗？

2022-04-16

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

JAMA N：DWI阳性者才能从双抗治疗中获益？

2022-04-13

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

双抗期间院外出血风险评估（PRECISE-DAPT score）

2022-03-17

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

阿司匹林 + 替格瑞洛，适合中国人群的双抗治疗！

2022-03-16

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Cell：复旦大学研究人员发现可雾化吸入的广谱抗新冠全人源纳米双抗药物

2022-03-13

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Stroke：穿支动脉粥样硬化病的双抗联合阿加曲班治疗

2022-02-21

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Annals of Neurology：天坛医院，轻度脑中风后，双抗血小板治疗，出血风险如何？

2022-02-17

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药

2021-12-12

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

君实生物JS016新冠双抗体疗法获得授权成为全球且唯一可在12岁以下人群中紧急使用的中和抗体疗法

2021-12-08

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Nature Communications：PD-1/CD137双抗效果优异，安全性良好

2021-11-16

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

JAMA N：NIHSS评分4和5分患者双抗治疗的证据

2021-10-15

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！

2021-09-12

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

乳腺癌抗体治疗格局：单抗/双抗/ADC百花齐放！

2021-09-04

科室
- - 订阅+
  - 更多科室
工具
服务